Aurinia Pharmaceuticals Inc. (AUPH), headquartered in Victoria, British Columbia, Canada, is one of the leading biopharmaceutical companies that specializes in the global development and commercialization of novel therapeutics for diseases that are orphan and under researched. AUPH's vision is to leverage its expertise and dedication towards changing lives and facilitating the needs of patients suffering from serious diseases worldwide.
Aurinia Pharmaceuticals’ portfolio is enveloped around Lupkynis™ (voclosporin), an innovative drug that is deemed best in implementing treatment for adults diagnosed with active lupus nephritis (LN). This was approved by the United States FDA in 2021. Lupus nephritis is a serious progression of systemic lupus erythematosus (SLE), a chronic and complex autoimmune disease. The introduction of Lupkynis transformed the treatment models, making it the first FDA-approved oral therapy for LN.
Apart from its main product, Aurinia also focuses on growing the product pipeline with other new potential treatments for other auto-immune diseases. The company strives to create a comprehensive suite of therapeutics specially designed to treat a range of debilitating diseases.
Aurinia Pharmaceuticals Inc. was founded in 1993, rebranded and relaunched in 2012. Since then, Aurinia has grown enormously, thanks to their team of experts who have been relentless in their pursuit of new therapeutics breakthroughs and best practices. The experienced management team at Aurinia is armed with deep industry knowledge and a track record of development and commercial success.
The company trades on the NASDAQ Global Market (NASDAQ) under the ticker symbol "AUPH" and on the Toronto Stock Exchange under the ticker symbol "AUP". This dual listing ensures the company is accessible to a broad range of investors, both in North America and beyond.
Aurinia Pharmaceuticals Inc. (AUPH) maintains a strong focus on research and development, keeping them at forefront of pharmaceutical innovation. Their commitment to improving patient outcomes and pioneering treatments for orphan diseases positions Aurinia as a significant player in the field of biopharmaceutical companies.
Aurinia’s passion for delivering impactful novel therapeutics along with their strategic market advances have created a promising trajectory for its future growth. AUPH's commitment to science and patients powers their vision for a healthier world, and their dedication in treating under-addressed diseases shows their ongoing potential in biopharmaceuticals industry.